Sukumar Nagendran Taysha Gene Therapies, Inc. (TSHA) insider trading activity

Sukumar Nagendran is President and Head of R&D of Taysha Gene Therapies, Inc.. Currently has a direct ownership of 1.01 Million shares of TSHA, which is worth approximately $4.24 Million. The most recent transaction as insider was on Dec 01, 2025, when has been sold 260,047 shares (Common Stock) at a price of $4.51 per share, resulting in proceeds of $1,172,811. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.01M

0% 3M change

12.1% 12M change

Total Value Held $4.24 Million

Sukumar Nagendran Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2025	SELL Open market or private sale	$1,172,811 $4.51 p/Share	260,047 Reduced 20.53%	1,006,439 Common Stock
Dec 01 2025	BUY Exercise of conversion of derivative security	$444,680 $1.71 p/Share	260,047 Added 17.04%	1,266,486 Common Stock
Nov 28 2025	SELL Open market or private sale	$523,093 $4.75 p/Share	110,125 Reduced 9.86%	1,006,439 Common Stock
Nov 28 2025	BUY Exercise of conversion of derivative security	$133,251 $1.21 p/Share	110,125 Added 8.98%	1,116,564 Common Stock
Sep 10 2025	SELL Open market or private sale	$646,000 $3.23 p/Share	200,000 Reduced 16.58%	1,006,439 Common Stock
Sep 10 2025	BUY Exercise of conversion of derivative security	$28,804 $0.7 p/Share	41,150 Added 3.3%	1,206,439 Common Stock
Aug 21 2025	SELL Open market or private sale	$162,603 $2.85 p/Share	57,054 Reduced 4.67%	1,165,289 Common Stock

Jan 02 2025	BUY Grant, award, or other acquisition	-	324,500 Added 20.98%	1,222,343 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	863,617 Added 49.03%	897,843 Common Stock
May 16 2023	BUY Open market or private purchase	$3,400 $0.68 p/Share	5,000 Added 12.75%	34,226 Common Stock
Feb 02 2022	BUY Open market or private purchase	$80,100 $8.01 p/Share	10,000 Added 25.49%	29,226 Common Stock
Sep 28 2020	BUY Conversion of derivative security	-	19,226 Added 50.0%	19,226 Common Stock

Also insider at

SLDB

Solid Biosciences Inc. Healthcare